Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases
Aim: Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that...
Saved in:
Published in | Nephrology (Carlton, Vic.) Vol. 11; no. 5; pp. 381 - 385 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Melbourne, Australia
Blackwell Publishing Asia
01.10.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim: Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years.
Methods: The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time‐course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal.
Results: The median patient age was 78 years. The mean baseline serum creatinine level was 83 µmol/L, peak level 392 µmol/L, and recovery level 139 µmol/L. The erythrocyte sedimentation rate (ESR) and C‐reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C‐reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6–18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure.
Conclusion: PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C‐reactive protein. |
---|---|
AbstractList | Aim: Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years.
Methods: The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time‐course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal.
Results: The median patient age was 78 years. The mean baseline serum creatinine level was 83 µmol/L, peak level 392 µmol/L, and recovery level 139 µmol/L. The erythrocyte sedimentation rate (ESR) and C‐reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C‐reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6–18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure.
Conclusion: PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C‐reactive protein. Aim: Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years. Methods: The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time‐course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal. Results: The median patient age was 78 years. The mean baseline serum creatinine level was 83 µmol/L, peak level 392 µmol/L, and recovery level 139 µmol/L. The erythrocyte sedimentation rate (ESR) and C‐reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C‐reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6–18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure. Conclusion: PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C‐reactive protein. Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to report and analyse the clinical features of 15 patients with acute interstitial nephritis (AIN) and acute renal failure from PPI that were referred to renal services in Auckland over a period of 3 years. The clinical presentation, therapeutic drugs, demographic details and renal outcome of the patients were considered. The population at risk and total PPI exposure were able to be defined. The diagnosis of AIN was made by renal biopsy in 12 cases. In all patients, the time-course of drug exposure and improvement of renal function on withdrawal suggested PPI were causal. The median patient age was 78 years. The mean baseline serum creatinine level was 83 micromol/L, peak level 392 micromol/L, and recovery level 139 micromol/L. The erythrocyte sedimentation rate (ESR) and C-reactive protein were elevated at the time of diagnosis in the 11 and 12 patients, respectively, where this information was collected (ESR mean 85 mm/h, and C-reactive protein mean 81 mg/L). AIN occurred at 8 per 100 000 patient years (95% confidence level 2.6-18.7 per 100 000 patient years). Although four patients presented with an acute systemic allergic reaction, 11 were asymptomatic with an insidious development of renal failure. PPI are now the most commonly identified cause of AIN in the Auckland area. Recovery occurs after withdrawal of the drug but is often incomplete. Early diagnosis may be facilitated by clinician awareness of the insidious onset of renal failure, and an elevated erythrocyte sedimentation rate and C-reactive protein. |
Author | PILMORE, HELEN SIMPSON, IAN J THEIN, HLA MANLEY, PAUL WILLIAMS, LAURIE MARSHALL, MARK R VOSS, DAVID |
Author_xml | – sequence: 1 givenname: IAN J surname: SIMPSON fullname: SIMPSON, IAN J email: i.simpson@auckland.ac.nz organization: Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland – sequence: 2 givenname: MARK R surname: MARSHALL fullname: MARSHALL, MARK R organization: Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland – sequence: 3 givenname: HELEN surname: PILMORE fullname: PILMORE, HELEN organization: Renal Service, Auckland City Hospital, and – sequence: 4 givenname: PAUL surname: MANLEY fullname: MANLEY, PAUL organization: Renal Service, Auckland City Hospital, and – sequence: 5 givenname: LAURIE surname: WILLIAMS fullname: WILLIAMS, LAURIE organization: Renal Service, Auckland City Hospital, and – sequence: 6 givenname: HLA surname: THEIN fullname: THEIN, HLA organization: Renal Service, Auckland City Hospital, and – sequence: 7 givenname: DAVID surname: VOSS fullname: VOSS, DAVID organization: Department of Renal Medicine, Middlemore Hospital, Auckland, New Zealand |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17014549$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkF1PwjAUhhuDkQ_9C6Z_YLPt2n0YbwxBNCFICEbumtKdhSJsSzsi_HuLI3hrk5O-ad_nXDx91CmrEhDClITUn4dNSDknAU2yJGSExKEfQcPDFepdPjo-R4wEIhJpF_Wd2xBCExbTG9SlCaFc8KyHljNbNVWJ6_2uxqZcm5VpKuuwKnOs9L4B_9iAdY1pjNriEuq19dE94jnUlW3aYqm2R2ccrgpMBdbKgbtF14XaOrg73wP08TJaDF-Dyfv4bfg8CTTPBA24EDGkWhGSc5IziHXKeMYpzUjGWMa0zmlRABF8FTOt_KRFSgA00CLhGqIBStu92lbOWShkbc1O2aOkRJ5kyY08OZEnJ_IkS_7KkgeP3rdovV_tIP8Dz3Z84aktfJstHP-9WE5HMx88HrS4cQ0cLriyXzJOokTIz-lYLuZLFsXDpcyiH993iXM |
CitedBy_id | crossref_primary_10_1186_s12882_016_0325_4 crossref_primary_10_1186_s12882_018_0848_y crossref_primary_10_1093_ndt_gfw470 crossref_primary_10_1590_2175_8239_jbn_2018_0021 crossref_primary_10_1186_s12882_017_0536_3 crossref_primary_10_1038_ki_2014_294 crossref_primary_10_3390_jcm12072467 crossref_primary_10_1093_ckj_sfad109 crossref_primary_10_1016_j_nephro_2017_06_005 crossref_primary_10_1016_j_amjms_2021_05_017 crossref_primary_10_1016_j_techsoc_2012_06_002 crossref_primary_10_1038_s41581_024_00854_w crossref_primary_10_1093_ndtplus_sfq146 crossref_primary_10_1097_MJT_0b013e31817149bf crossref_primary_10_1007_s13730_015_0204_z crossref_primary_10_1080_17425255_2018_1539076 crossref_primary_10_1111_j_1365_2125_2007_02927_x crossref_primary_10_1097_MJT_0000000000001368 crossref_primary_10_33667_2078_5631_2024_5_36_42 crossref_primary_10_1053_j_ajkd_2018_04_013 crossref_primary_10_1186_s40545_019_0167_0 crossref_primary_10_7759_cureus_49883 crossref_primary_10_1111_fcp_12451 crossref_primary_10_3390_jcm11164786 crossref_primary_10_1053_j_gastro_2010_08_023 crossref_primary_10_1136_bmjopen_2020_047059 crossref_primary_10_1016_j_cld_2014_05_003 crossref_primary_10_1517_14740330802410462 crossref_primary_10_1093_ndt_gfaa169 crossref_primary_10_1053_j_ajkd_2015_10_030 crossref_primary_10_1016_j_lpm_2012_09_016 crossref_primary_10_1097_MAJ_0000000000000323 crossref_primary_10_1097_MCG_0000000000001035 crossref_primary_10_2478_inmed_2020_0127 crossref_primary_10_1016_j_ekir_2017_01_005 crossref_primary_10_1038_ki_2014_74 crossref_primary_10_1177_2042098617715381 crossref_primary_10_15171_PS_2016_30 crossref_primary_10_1111_j_1365_2036_2007_03407_x crossref_primary_10_1016_j_biopha_2023_115149 crossref_primary_10_17533_udea_iatreia_45 crossref_primary_10_1053_j_ajkd_2014_04_027 crossref_primary_10_1007_s40266_014_0166_4 crossref_primary_10_1053_j_gastro_2008_08_044 crossref_primary_10_1186_s12882_020_02175_z crossref_primary_10_4081_cp_2018_1065 crossref_primary_10_1093_ndt_gfp751 crossref_primary_10_2215_CJN_11290821 crossref_primary_10_1007_s11033_023_08573_4 crossref_primary_10_1111_j_1440_1797_2006_00675_x crossref_primary_10_21763_tjfmpc_698985 crossref_primary_10_1681_nsap_2022_21_1_5 crossref_primary_10_5124_jkma_2020_63_1_30 crossref_primary_10_5858_133_2_268 crossref_primary_10_1155_2024_1317971 crossref_primary_10_1586_17512433_2013_811206 crossref_primary_10_1053_j_ackd_2010_12_001 crossref_primary_10_34067_KID_0001742021 crossref_primary_10_52711_0974_360X_2022_00026 crossref_primary_10_1056_NEJMcpc0804600 crossref_primary_10_2169_naika_112_51 crossref_primary_10_1159_000525561 crossref_primary_10_30895_2312_7821_2020_8_4_198_204 crossref_primary_10_1002_pds_3329 crossref_primary_10_1016_j_revmed_2008_02_001 crossref_primary_10_1097_MD_0000000000022509 crossref_primary_10_1093_ndtplus_sfn093 crossref_primary_10_1136_archdischild_2017_314026 crossref_primary_10_1177_1358863X14568444 crossref_primary_10_34067_KID_0007622021 crossref_primary_10_1007_s00104_011_2173_x crossref_primary_10_2478_inmed_2020_0140 crossref_primary_10_1097_MD_0000000000003363 crossref_primary_10_2169_naika_107_872 crossref_primary_10_1038_sj_ki_5002038 crossref_primary_10_1007_s40620_016_0309_2 crossref_primary_10_1016_j_cegh_2017_12_008 crossref_primary_10_1038_s41598_023_48430_9 crossref_primary_10_1111_nep_12226 crossref_primary_10_1681_ASN_2016020192 crossref_primary_10_1016_j_drudis_2009_03_014 crossref_primary_10_1007_s40264_022_01181_4 crossref_primary_10_4068_cmj_2023_59_2_115 crossref_primary_10_4103_ijn_IJN_397_20 crossref_primary_10_1016_j_kint_2022_06_007 crossref_primary_10_32818_reccmi_a6n3a5 crossref_primary_10_3892_etm_2018_6088 crossref_primary_10_1007_s11255_011_9972_3 crossref_primary_10_1053_j_ackd_2016_11_016 crossref_primary_10_1186_1471_2369_14_150 crossref_primary_10_3389_fphar_2022_957980 crossref_primary_10_1093_ckj_sfz097 crossref_primary_10_1097_SMJ_0b013e3181f6539d crossref_primary_10_1111_j_1365_2125_2010_03623_x crossref_primary_10_1161_CIRCULATIONAHA_113_003602 crossref_primary_10_15171_npj_2017_02 |
Cites_doi | 10.1093/ndt/gfh137 10.1111/j.1572-0241.2001.05345.x 10.1345/aph.1D085 10.1093/ndt/gfh485 10.5694/j.1326-5377.2005.tb06675.x 10.1111/j.1440-1797.2005.00365.x 10.1016/0002-9343(92)90181-A 10.1093/ndt/15.9.1450 10.1001/archinte.137.8.997 |
ContentType | Journal Article |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1111/j.1440-1797.2006.00651.x |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1440-1797 |
EndPage | 385 |
ExternalDocumentID | 10_1111_j_1440_1797_2006_00651_x 17014549 NEP651 ark_67375_WNG_TRX236CX_9 |
Genre | article Journal Article |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1OB 1OC 29M 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABHUG ABJNI ABPTK ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFVGU AFZJQ AGJLS AHBTC AHEFC AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO KMS LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOQ WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 XVB YFH ZZTAW ~IA ~WT AITYG HGLYW OIG CGR CUY CVF ECM EIF NPM AAYXX CITATION |
ID | FETCH-LOGICAL-c4951-4556e8ca00d40d2e6c82494119092292ccd1ffe054b62ca62c8f80eece1f74ce3 |
IEDL.DBID | DR2 |
ISSN | 1320-5358 |
IngestDate | Fri Aug 23 01:58:07 EDT 2024 Thu May 23 23:13:24 EDT 2024 Sat Aug 24 01:00:05 EDT 2024 Wed Jan 17 05:06:04 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4951-4556e8ca00d40d2e6c82494119092292ccd1ffe054b62ca62c8f80eece1f74ce3 |
Notes | ark:/67375/WNG-TRX236CX-9 ArticleID:NEP651 istex:0F38913D54E3BE9355054B5D3D7D3BCA671EAD8A |
PMID | 17014549 |
PageCount | 5 |
ParticipantIDs | crossref_primary_10_1111_j_1440_1797_2006_00651_x pubmed_primary_17014549 wiley_primary_10_1111_j_1440_1797_2006_00651_x_NEP651 istex_primary_ark_67375_WNG_TRX236CX_9 |
PublicationCentury | 2000 |
PublicationDate | October 2006 |
PublicationDateYYYYMMDD | 2006-10-01 |
PublicationDate_xml | – month: 10 year: 2006 text: October 2006 |
PublicationDecade | 2000 |
PublicationPlace | Melbourne, Australia |
PublicationPlace_xml | – name: Melbourne, Australia – name: Australia |
PublicationTitle | Nephrology (Carlton, Vic.) |
PublicationTitleAlternate | Nephrology (Carlton) |
PublicationYear | 2006 |
Publisher | Blackwell Publishing Asia |
Publisher_xml | – name: Blackwell Publishing Asia |
References | Clarkson MR, Giblin L, O'Connell FP et al. Acute interstitial nephritis: Clinical features and response to corticosteroid therapy. Nephrol. Dial. Transplant. 2004; 19: 2778-83. Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. Am. J. Gastroenterol. 2001; 96: 3428-31. Wall CA, Gaffney EF, Mellotte GJ. Hypercalcaemia and acute interstitial nephritis associated with omeprazole therapy. Nephrol. Dial. Transplant. 2000; 15: 1450-52. Ruffenach SJ, Siskind MS, Lien YH. Acute interstitial nephritis due to omeprazole. Am. J. Med. 1992; 93: 472-3. Ra A, Tobe SW. Acute interstitial nephritis due to pantoprazole. Ann. Pharmacother. 2004; 38: 41-5. Geevasinga N, Coleman PL, Roger SD. Rabeprazole-induced acute interstitial nephritis. Nephrology 2005; 10: 7-9. Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: Experience from a single UK renal unit. Nephrol. Dial. Transplant. 2004; 19: 1441-6. Petersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9. Moore I, Sayer JA, Nayar A et al. Pantoprazole-induced acute interstitial nephritis. J. Nephrol. 2004; 17: 580-81. Nolan CM, Abernathy RS. Nephropathy associated with methicillin therapy: Prevalence and determinants in patients with staphylococcal bacteraemia. Arch. Intern. Med. 1977; 137: 997-1000. Geevasinga N, Kairaitis L, Rangan GK et al. Acute interstitial nephritis secondary to esomeprazole. Med. J. Aust. 2005; 182: 235-6. Delve P, Lau M, Yun K, Walker R. Omeprazole-induced acute interstitial nephritis. N. Z. Med. J. 2003; 116: U332. National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Quality Initiative. Am. J. Kidney Dis. 2002; 39 (Suppl. 2): S1-246. 2002; 39 1994; 344 2005; 10 2005; 182 1977; 137 2003; 116 2000; 15 2004; 19 2004; 38 2004; 17 1992; 93 2001; 96 17014548 - Nephrology (Carlton). 2006 Oct;11(5):379-80 Petersen TR (e_1_2_6_13_2) 1994; 344 Delve P (e_1_2_6_6_2) 2003; 116 Moore I (e_1_2_6_8_2) 2004; 17 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_5_2 e_1_2_6_12_2 e_1_2_6_2_2 e_1_2_6_10_2 National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board. (e_1_2_6_11_2) 2002; 39 e_1_2_6_14_2 |
References_xml | – volume: 96 start-page: 3428 year: 2001 end-page: 31 article-title: Acute interstitial nephritis due to omeprazole publication-title: Am. J. Gastroenterol. – volume: 344 start-page: 1383 year: 1994 end-page: 9 article-title: Randomised trial of cholesterol lowering in patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S) publication-title: Lancet – volume: 38 start-page: 41 year: 2004 end-page: 5 article-title: Acute interstitial nephritis due to pantoprazole publication-title: Ann. Pharmacother. – volume: 19 start-page: 1441 year: 2004 end-page: 6 article-title: Drug‐induced tubulo‐interstitial nephritis secondary to proton pump inhibitors: Experience from a single UK renal unit publication-title: Nephrol. Dial. Transplant. – volume: 137 start-page: 997 year: 1977 end-page: 1000 article-title: Nephropathy associated with methicillin therapy: Prevalence and determinants in patients with staphylococcal bacteraemia publication-title: Arch. Intern. Med. – volume: 116 start-page: U332 year: 2003 article-title: Omeprazole‐induced acute interstitial nephritis publication-title: N. Z. Med. J. – volume: 17 start-page: 580 year: 2004 end-page: 81 article-title: Pantoprazole‐induced acute interstitial nephritis publication-title: J. Nephrol. – volume: 10 start-page: 7 year: 2005 end-page: 9 article-title: Rabeprazole‐induced acute interstitial nephritis publication-title: Nephrology – volume: 182 start-page: 235 year: 2005 end-page: 6 article-title: Acute interstitial nephritis secondary to esomeprazole publication-title: Med. J. Aust. – volume: 15 start-page: 1450 year: 2000 end-page: 52 article-title: Hypercalcaemia and acute interstitial nephritis associated with omeprazole therapy publication-title: Nephrol. Dial. Transplant. – volume: 19 start-page: 2778 year: 2004 end-page: 83 article-title: Acute interstitial nephritis: Clinical features and response to corticosteroid therapy publication-title: Nephrol. Dial. Transplant. – volume: 39 start-page: S1 issue: Suppl. 2 year: 2002 end-page: 246 article-title: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Quality Initiative publication-title: Am. J. Kidney Dis. – volume: 93 start-page: 472 year: 1992 end-page: 3 article-title: Acute interstitial nephritis due to omeprazole publication-title: Am. J. Med. – volume: 39 start-page: S1 issue: 2 year: 2002 ident: e_1_2_6_11_2 article-title: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Quality Initiative publication-title: Am. J. Kidney Dis. contributor: fullname: National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board. – volume: 17 start-page: 580 year: 2004 ident: e_1_2_6_8_2 article-title: Pantoprazole‐induced acute interstitial nephritis publication-title: J. Nephrol. contributor: fullname: Moore I – ident: e_1_2_6_5_2 doi: 10.1093/ndt/gfh137 – ident: e_1_2_6_3_2 doi: 10.1111/j.1572-0241.2001.05345.x – ident: e_1_2_6_7_2 doi: 10.1345/aph.1D085 – ident: e_1_2_6_14_2 doi: 10.1093/ndt/gfh485 – ident: e_1_2_6_10_2 doi: 10.5694/j.1326-5377.2005.tb06675.x – ident: e_1_2_6_9_2 doi: 10.1111/j.1440-1797.2005.00365.x – volume: 116 start-page: U332 year: 2003 ident: e_1_2_6_6_2 article-title: Omeprazole‐induced acute interstitial nephritis publication-title: N. Z. Med. J. contributor: fullname: Delve P – volume: 344 start-page: 1383 year: 1994 ident: e_1_2_6_13_2 article-title: Randomised trial of cholesterol lowering in patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S) publication-title: Lancet contributor: fullname: Petersen TR – ident: e_1_2_6_2_2 doi: 10.1016/0002-9343(92)90181-A – ident: e_1_2_6_4_2 doi: 10.1093/ndt/15.9.1450 – ident: e_1_2_6_12_2 doi: 10.1001/archinte.137.8.997 |
SSID | ssj0017261 |
Score | 2.1698809 |
Snippet | Aim: Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study... Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study was to... Aim: Although proton pump inhibitors (PPI) are usually safe and effective therapeutic agents, serious adverse effects can occur. The aim of the present study... |
SourceID | crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 381 |
SubjectTerms | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects acute interstitial nephritis Acute Kidney Injury - chemically induced Acute Kidney Injury - epidemiology Acute Kidney Injury - pathology Aged Aged, 80 and over Anti-Ulcer Agents - adverse effects Biopsy Blood Sedimentation C-Reactive Protein - metabolism Enzyme Inhibitors - adverse effects Female Humans Male Middle Aged Nephritis, Interstitial - chemically induced Nephritis, Interstitial - epidemiology Nephritis, Interstitial - pathology omeprazole Omeprazole - adverse effects pantoprazole Proton Pump Inhibitors renal failure Risk Factors tubulo-interstitial nephritis |
Title | Proton pump inhibitors and acute interstitial nephritis: Report and analysis of 15 cases |
URI | https://api.istex.fr/ark:/67375/WNG-TRX236CX-9/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1440-1797.2006.00651.x https://www.ncbi.nlm.nih.gov/pubmed/17014549 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwEA-iIL74_TG_yIP41tGPJE19E5mKsCGi2LeSJlccg27MDcS_3ru2m1N8EPGhEGhzJcld7nfJ5RfGzkIHEhJAQ3J-7AknI8-YQnhKC-cSECYGWhro9tTtk7hLZdrkP9FZmJofYr7gRpZRzddk4CZ__WbktC8ZJ_FsT0HJoE14knj1CB89zJmk0E2rYHZgWEZSf03q-VHQF0-1Qp3-tuCmFqFs5YuuN9hg1oo6BWXQnk7ytn3_RvD4P83cZOsNZOWXtY5tsSUot9lqt9mU32Hp_XiICJKPUDN4v3zp5326woeb0nFjpxPgxEkxpqQEVHZeAuoPMSld8Br91x825Ch8WPBAcovO9XWXPV13Hq9uvebCBs9inIWxqJQKtDW-74TvQlBWY3QnAgQdSRgmobUuKApAlJir0Bp8dKF9AAtBEQsL0R5bLoclHDAeau1QkPKTyIgCpRKJTITTkSi0BKlaLJgNTjaqeTmyxXhGYBm7jG7ZpLw97LLsrcXOq1GcVzDjAeW1xTJ77t1kjw9pGKmrNEtabL8e5k_RMW2_Cnwjq8H69T-zXuceC4d_rHfE1qo1nyp78JgtT8ZTOEEUNMlPK_3-ADhq9qU |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1dS8MwMIiC-uL3x_zMg_jW0Y8kTX0TUefHhsjEvpUsueKYdGNuMPz1XtpubsMHER8KgTZXkrvLfeaOkDPfAIcIkJGMGzrM8MBRKmWOkMyYCJgKwboG6g1Re2H3MY_LdkD2LkxRH2LicLOckZ_XlsGtQ3qOy21gMozCcVBBcK-KCuUScj_P7avnSS0pFNTCG18Z5gGXs2k9P0KakVVLdttHU4JqWpnNpdHNOnkfr6NIQulUh4NWVX_OlXj8p4VukLVSa6WXBZltkgXItshyvYzLb5P4qd9FJZL2kDhoO3trt9q2iw9VmaFKDwdAbVmKvs1LQHqnGSAJ2WJKF7QwAIoPy_ootJtSj1ON8vVjh7zcXDevak7Zs8HRaGqhOcq5AKmV6xrmGh-ElmjgMQ_1jsj3I19r46UpoKLYEr5W-MhUugAavDRkGoJdsph1M9gn1JfSICDhRoFiKUK1dWQCPJFYKjlwUSHeGDtJryjNkUybNAzHuGW20aZN3cMtS0YVcp6jcTJB9Ts2tS3kyWvjNmk-x34gruIkqpC9As_foEMbgWX4hufY-vU_k8b1Ew4O_jjvlKzUmvXH5PGu8XBIVnMXUJ5MeEQWB_0hHKNSNGid5MT-BdSZ-sc |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS-wwEA-iIF6eH8_3XD9zeHjr0qZJmnoTdf1eFlHsrWSTCS4L3WXdBfGvd9J211U8yMNDIdBmSjIzmZnM5BdC_jELAlJARbJhEnAr4kBrxwOpuLUpcJ2A3xq4bcuLB36Viayuf_JnYSp8iNmGm9eMcr32Cj607pOS-7xkkibTnIIUURP9ySUuY-Yl_PRuBiWFdlpG0xPDIhbqY1XPl5Q-mKolP-svc3Zq3pctjVFrlfSnw6hqUPrNybjbNK-fEB5_Zpxr5Ffts9LjSsjWyQIUG2T5ts7K_yZZZzRAF5IOUTRor3jqdXv-Dh-qC0u1mYyBelCKka9KQGmnBaAAeSilI1q5_9WHNToKHTgaCWrQuj5vkofW2f3JRVDf2BAYDLQwGBVCgjI6DC0PLQNpFIZ3PEKvI2UsZcbYyDlAN7ErmdH4KKdCAAORS7iB-A9ZLAYFbBHKlLJISIZprLlDqh5FJsb1iDslQMgGiabMyYcVMEc-H9BwbOOU-Ws2feEeTln-0iCHJRdnHfSo7wvbEpE_ts_z-7uMxfIky9MG-Vux-Z104vOvHN-Iklnf_mfePutgY_s_-x2Q5c5pK7-5bF_vkJVy_6esJNwli-PRBPbQIxp390tRfwPTQfl2 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proton+pump+inhibitors+and+acute+interstitial+nephritis%3A+Report+and+analysis+of+15+cases&rft.jtitle=Nephrology+%28Carlton%2C+Vic.%29&rft.au=SIMPSON%2C+IAN+J&rft.au=MARSHALL%2C+MARK+R&rft.au=PILMORE%2C+HELEN&rft.au=MANLEY%2C+PAUL&rft.date=2006-10-01&rft.pub=Blackwell+Publishing+Asia&rft.issn=1320-5358&rft.eissn=1440-1797&rft.volume=11&rft.issue=5&rft.spage=381&rft.epage=385&rft_id=info:doi/10.1111%2Fj.1440-1797.2006.00651.x&rft.externalDBID=10.1111%252Fj.1440-1797.2006.00651.x&rft.externalDocID=NEP651 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1320-5358&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1320-5358&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1320-5358&client=summon |